Table 6 Projections of future annual sales in Germany for reserve antimicrobials.
From: Changes in revenues associated with antimicrobial reimbursement reforms in Germany
|  | Tenth year from introduction to Germany | Cumulative revenue at patent end if growth continues along a linear trend | Gap compared to “Fair Share” 10-year pull incentive |
|---|---|---|---|
Avibactam/Ceftazidime | 2027 | €64,552,418 | €185,447,582 |
Cefiderocol | 2031 | €64,026,732 | €185,973,268 |
